Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

PHASE3CompletedINTERVENTIONAL
Enrollment

1,312

Participants

Timeline

Start Date

March 17, 2020

Primary Completion Date

May 20, 2020

Study Completion Date

May 20, 2020

Conditions
Corona Virus InfectionAcute Respiratory Distress SyndromeSARS-CoV InfectionCoronavirusCoronavirus Infections
Interventions
DRUG

Hydroxychloroquine

200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days

OTHER

Placebo

4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days

Trial Locations (5)

55455

Nationwide Enrollment via Internet, please email: [email protected], Minneapolis

University of Minnesota, Minneapolis

Unknown

University of Alberta, Edmonton

University of Manitoba, Winnipeg

Research Institute of the McGill University Heath Centre, Montreal

All Listed Sponsors
collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

collaborator

University of Manitoba

OTHER

collaborator

University of Alberta

OTHER

lead

University of Minnesota

OTHER

NCT04308668 - Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 | Biotech Hunter | Biotech Hunter